JATT Acquisition
JATTZura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases.
Competitors
By market cap
By revenue growth
Profile
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases. The company identifies immune-mediated diseases where translational and clinical evidence supports specific biological pathways, targeting conditions with significant unmet medical needs. Its core strategy involves advancing multi-target and single-target antibody-based therapies to achieve durable disease control.
A clinical-stage developer of differentiated bispecific and monoclonal antibodies targeting IL-17A, BAFF, IL-7Rα, and IL-33 pathways.
FAQ
- What is JATT Acquisition's market cap?
- JATT Acquisition (JATT) has a market capitalization of $96.8M and trades on XNYS.
- Who are JATT Acquisition's competitors?
- JATT Acquisition's key competitors include AbbVie Inc., Amgen Inc., Zenas BioPharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does JATT Acquisition partner with?
- JATT Acquisition's notable partners include Eli Lilly and Company, Pfizer Inc., Lonza Sales AG, and others.
- What subsidiaries does JATT Acquisition have?
- JATT Acquisition's subsidiaries include ZB17 LLC, Z33 Bio Inc., Zura Bio UK.
- Where is JATT Acquisition headquartered?
- JATT Acquisition is headquartered in Cayman Islands and employs approximately 3 people. It has been publicly traded since 2026.